Cipla Inaugurates India’s Pioneer Comprehensive Lung Wellness Facility in Delhi
Cipla, a leading pharmaceutical company, has launched India’s first fully integrated Breathefree Lung Wellness Center in Delhi. The center, located in Lajpat Nagar, offers a comprehensive range of services, including over 60 diagnostic tests, pulmonary rehabilitation, nutrition support, and smoking cessation counseling. The goal of the center is to address the critical gap in India’s respiratory care ecosystem by providing advanced, standardized lung diagnostics at an affordable price.
The launch of the center is timely, given India’s growing burden of chronic respiratory diseases, which affects an estimated 90 million people. Many patients remain undiagnosed or misdiagnosed due to limited access to specialized diagnostic infrastructure and high-quality pulmonary testing. The center’s diagnostic tests cover various aspects of lung health, including lung physiology, microbiology, immunology, blood chemistry, and radiology.
In addition to diagnostics, the center provides pulmonary rehabilitation, nutritional support, and smoking cessation counseling. The center will also function as a training and certification hub for healthcare professionals and facilitate research in respiratory sciences. According to Achin Gupta, Global COO of Cipla, the center addresses a critical gap in the diagnostic landscape and aims to make high-quality, standardized lung diagnostics accessible to doctors and patients across India.
The launch of the center coincides with Cipla’s 90th anniversary year, signaling the company’s commitment to expanding beyond pharmaceuticals into diagnostics and patient-management services. The center’s launch is also significant, given Delhi’s recent severe air pollution, which has exacerbated respiratory problems. With the Breathefree Lung Wellness Center, Cipla hopes to improve early diagnosis, treatment, and overall respiratory health for patients across India.
The center’s services include spirometry, oscillometry, DLCO, body plethysmography, FeNO, CPET, sleep studies, X-rays, and CT scans, all conducted by trained technicians following globally recognized protocols. The center’s team, led by Chief Medical Officer Jaideep Gogtay, aims to provide accurate and timely diagnosis, which is key to reducing hospitalization and improving patient outcomes. Overall, the Breathefree Lung Wellness Center is a significant step towards addressing India’s growing respiratory health needs and providing accessible, high-quality lung diagnostics and care.
Lupin’s chart patterns reveal a Golden Cross formation, hinting at a possible upcoming bullish trend reversal.
The Golden Cross is a technical indicator that suggests a trend reversal from bearish to bullish, occurring when the 50-day moving average (DMA) moves above the 200 DMA. For Lupin, a pharmaceutical company, this event may mark the beginning of a recovery phase after a period of mixed performance. Despite a year-to-date decline of 11.48%, Lupin has recorded gains of 8.32% and 9.39% over the past month and three months, respectively, outpacing the Sensex’s returns.
Technical indicators, such as the daily moving averages, Moving Average Convergence Divergence (MACD), and Bollinger Bands, support the bullish outlook. The On-Balance Volume (OBV) indicators also lean towards bullishness, suggesting that trading volumes support upward price movement. However, monthly MACD and KST indicators present a mildly bearish tone, indicating some caution in the longer term.
Lupin’s longer-term performance is mixed, with a three-year return of 183.63% and a five-year return of 133.35%, outperforming the Sensex. However, the 10-year performance shows Lupin lagging behind the Sensex. The current market capitalization of Rs 94,870 crore places Lupin in the large-cap category, which tends to exhibit more stable price movements.
Valuation metrics suggest that Lupin’s price-to-earnings (P/E) ratio is below the industry average, making it an attractive option for investors seeking exposure to the sector at a moderate valuation level. The formation of the Golden Cross can attract increased attention from traders and investors, but it is essential to consider this signal alongside other market factors and fundamental data.
Investors should factor in sector dynamics and consider Lupin’s valuation and medium-term returns. The Golden Cross event adds a compelling technical dimension to Lupin’s market assessment, signaling a potential bullish breakout. While longer-term indicators remain mixed, Lupin’s valuation and medium-term returns provide a context that could support further gains if market conditions remain favorable. Market participants should monitor Lupin’s price action and volume trends closely, considering the Golden Cross as part of a broader analytical framework.
Afghanistan-based company inks $100 million agreement with Indian pharma firm
The Taliban-led government in Afghanistan has signed a significant trade agreement with Indian pharmaceutical company Zydus Lifesciences, marking a shift in the country’s trade posture. The $100 million memorandum of understanding was signed between Afghanistan’s Roufi International Group and Zydus Lifesciences in Dubai, in the presence of the Taliban’s ambassador to the UAE. Under the deal, Zydus will export medical products to Afghanistan and is expected to open a local office and begin domestic manufacturing in the country.
This agreement comes after the Taliban imposed a ban on importing pharmaceutical products from neighboring Pakistan, citing concerns over quality and dependency. The Taliban-run Ministry of Finance had given Afghan traders a three-month window to transition to alternative sources, in a move seen as a response to deteriorating political and security ties between Kabul and Islamabad.
The deal with Zydus follows a visit to India by Taliban commerce minister Nooruddin Azizi, who led a delegation to New Delhi at the invitation of the Indian government. This marks a significant development in Afghanistan’s trade relations, as the country seeks to diversify its imports and reduce its dependence on Pakistan.
The agreement is expected to have a positive impact on Afghanistan’s healthcare sector, with Zydus Lifesciences being one of India’s largest publicly listed pharmaceutical firms. The company’s products will help meet the medical needs of the Afghan people, and the establishment of a local office and manufacturing facility will create jobs and stimulate economic growth.
The Taliban’s decision to curtail imports from Pakistan and engage with Indian companies reflects a significant shift in the country’s trade policy. As Afghanistan seeks to rebuild its economy and improve its trade relations, it is likely to explore new partnerships and opportunities with countries like India. The agreement with Zydus Lifesciences is a notable example of this shift, and it remains to be seen how this will impact the country’s trade relations with its neighbors and the wider region.
Sun Pharmaceutical Industries has secured approval from the US Food and Drug Administration for an updated label of UNLOXCYT, incorporating long-term efficacy data for Cutaneous Squamous Cell Carcinoma treatment.
Sun Pharmaceutical Industries Ltd. has received approval from the US Food and Drug Administration (USFDA) for an updated label for its medication UNLOXCYT (tretinoin), which is used to treat a rare skin condition called Cutaneous Squamous Cell Carcinoma (CSCC) in patients with advanced renal cell carcinoma (RCC). The updated label includes long-term efficacy data, demonstrating the treatment’s effectiveness in preventing the progression of CSCC.
UNLOXCYT is a topical formulation of tretinoin, a retinoid that has been shown to inhibit the growth of cancer cells. The medication is specifically designed to treat CSCC, a type of skin cancer that can occur in patients with advanced RCC. The condition is often aggressive and can lead to significant morbidity and mortality if left untreated.
The updated label includes data from a long-term study that evaluated the efficacy of UNLOXCYT in preventing the progression of CSCC in patients with advanced RCC. The study demonstrated that treatment with UNLOXCYT significantly reduced the risk of CSCC progression compared to placebo. The data also showed that UNLOXCYT was well-tolerated, with a safety profile consistent with previous studies.
The approval of the updated label is a significant milestone for Sun Pharma, as it provides healthcare providers with additional confidence in the long-term efficacy of UNLOXCYT in treating CSCC. The company believes that the updated label will help to increase awareness and adoption of the medication among healthcare providers and patients.
The USFDA approval is also a testament to Sun Pharma’s commitment to developing innovative treatments for rare and debilitating diseases. The company has a strong portfolio of specialty and generic products, and is dedicated to improving the lives of patients around the world.
In a statement, a spokesperson for Sun Pharma said, “We are pleased to receive USFDA approval for the updated UNLOXCYT label, which includes long-term efficacy data demonstrating the treatment’s effectiveness in preventing the progression of CSCC. This approval is a significant milestone for our company, and we believe it will help to increase awareness and adoption of UNLOXCYT among healthcare providers and patients.” The updated label is expected to be available in the US market shortly.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.